Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Receivables (2022 - 2025)

Dianthus Therapeutics has reported Receivables over the past 4 years, most recently at $5.0 million for Q3 2025.

  • Quarterly results put Receivables at $5.0 million for Q3 2025, up 85.87% from a year ago — trailing twelve months through Sep 2025 was $5.0 million (up 85.87% YoY), and the annual figure for FY2024 was $807000.0, up 63.36%.
  • Receivables for Q3 2025 was $5.0 million at Dianthus Therapeutics, up from $39000.0 in the prior quarter.
  • Over the last five years, Receivables for DNTH hit a ceiling of $5.6 million in Q4 2022 and a floor of $39000.0 in Q2 2025.
  • Median Receivables over the past 4 years was $917500.0 (2024), compared with a mean of $1.9 million.
  • Biggest five-year swings in Receivables: skyrocketed 258.19% in 2024 and later crashed 97.62% in 2025.
  • Dianthus Therapeutics' Receivables stood at $5.6 million in 2022, then tumbled by 91.18% to $494000.0 in 2023, then surged by 63.36% to $807000.0 in 2024, then surged by 519.58% to $5.0 million in 2025.
  • The last three reported values for Receivables were $5.0 million (Q3 2025), $39000.0 (Q2 2025), and $1.0 million (Q1 2025) per Business Quant data.